Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
Standard
Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. / von Felden, Johann; Schulze, Kornelius; Krech, Till; Ewald, Florian; Nashan, Björn; Pantel, Klaus; Lohse, Ansgar W; Riethdorf, Sabine; Wege, Henning.
In: ONCOTARGET, Vol. 8, No. 52, 27.10.2017, p. 89978-89987.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection
AU - von Felden, Johann
AU - Schulze, Kornelius
AU - Krech, Till
AU - Ewald, Florian
AU - Nashan, Björn
AU - Pantel, Klaus
AU - Lohse, Ansgar W
AU - Riethdorf, Sabine
AU - Wege, Henning
PY - 2017/10/27
Y1 - 2017/10/27
N2 - Background: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM-positive circulating tumor cells (CTC) as liquid biomarker to identify patients with high risk of recurrence after liver resection.Methods: 61 patients undergoing resection between 2011 and 2015 were consecutively enrolled. Blood specimens were obtained prior to surgery and processed with the CellSearchTM system, detecting EpCAM-positive CTC. The primary endpoint was recurrence-free survival (RFS).Results: 13 women and 44 men (63.6 ± 11.1 years) were finally evaluated. CTC-positive patients had a significantly higher risk of recurrence with a hazard ratio (HR) of 2.3 (p=0.027), and a shorter RFS compared to CTC-negative patients (5.0 ± 1.5 vs. 12.0 ± 2.5 months, p=0.039). As expected, incomplete resection (R1) was also associated with shorter RFS (HR=2.6, p=0.035), but vascular invasion was not. However, the predictive power of CTC status was independent of R1.Conclusion: Bloodstream detection of CTC prior to curative-intended liver resection discloses an elevated risk of HCC recurrence and could identify patients, who might benefit from adjuvant treatment.
AB - Background: Early hepatocellular carcinoma (HCC) has a limited prognosis due to recurrence rates of more than 50% after liver resection. Recurrence within two years is believed to be caused by untraceable micro metastases at the time of resection. The objective of this study was to investigate EpCAM-positive circulating tumor cells (CTC) as liquid biomarker to identify patients with high risk of recurrence after liver resection.Methods: 61 patients undergoing resection between 2011 and 2015 were consecutively enrolled. Blood specimens were obtained prior to surgery and processed with the CellSearchTM system, detecting EpCAM-positive CTC. The primary endpoint was recurrence-free survival (RFS).Results: 13 women and 44 men (63.6 ± 11.1 years) were finally evaluated. CTC-positive patients had a significantly higher risk of recurrence with a hazard ratio (HR) of 2.3 (p=0.027), and a shorter RFS compared to CTC-negative patients (5.0 ± 1.5 vs. 12.0 ± 2.5 months, p=0.039). As expected, incomplete resection (R1) was also associated with shorter RFS (HR=2.6, p=0.035), but vascular invasion was not. However, the predictive power of CTC status was independent of R1.Conclusion: Bloodstream detection of CTC prior to curative-intended liver resection discloses an elevated risk of HCC recurrence and could identify patients, who might benefit from adjuvant treatment.
KW - Journal Article
U2 - 10.18632/oncotarget.21208
DO - 10.18632/oncotarget.21208
M3 - SCORING: Journal article
C2 - 29163804
VL - 8
SP - 89978
EP - 89987
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 52
ER -
